Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a severe life-threatening disorder, characterized by hyperactivation of macrophages due to uncontrolled hypersecretion of inflammatory cytokines. Patients with HLH have a wide clinical spectrum but typically present with high fever, splenomegaly, cytopenias, coagulation abnormalities, and tissue evidence of hemophagocytosis.
1,2 HLH can be classified into two distinct forms: familial hemophagocytic lymphohistiocytosis (primary HLH) and secondary hemophagocytic lymphohistiocytosis (secondary HLH). 3, 4 Secondary HLH is associated with various conditions including infections, connective tissue diseases, and hematological malignancies, mainly non-Hodgkin's lymphoma (NHL). 5, 6 Large studies have suggested that natural killer (NK)/T-cell lymphoma is the predominant trigger of lymphoma-associated hemophagocytic syndrome (LAHS) in Asia. 7, 8 NK/T-cell lymphoma includes two subtypes:
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liu et al upper aerodigestive tract NK/T-cell lymphoma (UNKTL) and extra-upper aerodigestive tract NK/T-cell lymphoma (EUNKTL). 9 Briefly, UNKTL comprised all lymphomas confined to nasal cavity, nasopharynx, and the upper aerodigestive tract, whereas EUNKTL included lymphomas occurring at all other sites. Due to the rarity and heterogeneity of HLH, there have been few investigations with large sample size of NK/Tcell LAHS. In this retrospective study, we analyzed the clinical records of 28 patients with extranodal NK/T-cell lymphomaassociated HLH, in an attempt to have better understanding of the clinical characteristics and prognostic factors of the disease.
Patients and methods
A total of 28 patients who were diagnosed as extranodal NK/Tcell lymphoma-associated HLH and treated in Shanghai Cancer Center, China from January 2006 to July 2017, were included in this retrospective study. This study was approved by the Institutional Review Board of the Fudan University Shanghai Cancer Center. All patients signed separate informed consent forms for reviewing their medical records and research. All pathological results were reviewed by experienced pathologists in pathology department of Shanghai Cancer Center. All patients were pathologically confirmed of NK/T-cell lymphoma through biopsy samples according to the criteria of the WHO. 10 HLH was diagnosed according to the criteria proposed by the Histiocyte Society in 2004. 2 In the absence of a known gene mutation, a diagnosis of HLH can be made with at least five of the following eight criteria: fever, splenomegaly, cytopenias in two or more cell lines, hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis, low or absent activity in NK cells, ferritin concentration >500 µg/L, or soluble CD25 concentration >2,400 U/mL. The demographic details and clinical and laboratory features of the patients are summarized in Table  1 . For each patient, the following data before or at the time of HLH diagnosis were collected: patient demographics, UNKTL or EUNKTL, Ann Arbor stage, NK/T-cell lymphoma prognostic index (NKPI) score, 11 Eastern Cooperative Oncology Group (ECOG) performance score, fever, bone marrow involvement, laboratory tests, type of treatment, and survival status.
statistical analyses
All analyses were performed using PASW statistics 18 (SPSS Inc., Chicago, IL, USA). Overall survival (OS) was measured from the date of diagnosis to the date of death owing to any cause or the date of last follow-up. Patients who died within 2 weeks after diagnosis of NK/T-cell LAHS were defined as short survival group, and those who survived >2 months were defined as long survival group. Chi-squared test was used to 
Results
Patient characteristics
All 28 cases were from hospitalized patients, of whom 18 (64.3%) were men and 10 (35.7%) were women. 12 Thirteen patients with refractory or relapsing disease were treated with asparaginase-based regimen as salvage therapy achieved an ORR of 28.6%. The median time from diagnosis of NK/T-cell lymphoma to the onset of HLH was 9 months (1-228 months) . After the onset of HLH, patients were treated with chemotherapy following the HLH-2004 guideline proposed by the Histiocyte Society. The remission rate of the treatment was 23.8% (5/21), and statistically significant difference was found between clinical response to treatment and patients' OS (P=0.00021). One patient in our study received allo-allogeneic hematopoietic stem cell transplant after treatment of HLH and was still alive at the time of last follow-up. The interval between the diagnosis of NK/T-cell LAHS and death/last contact was between 4 and 701 days with the median interval of 15 days (Figure 1 ).
Comparison of patients' characteristics between the longer survival group and the shorter survival group
In our study, we divided patients into two groups: patients died within 2 weeks after diagnosis of NK/T-cell LAHS were defined as short survival group (n=13), and those who survived >2 months after diagnosis of NK/T-cell LAHS were defined as long survival group (n=6). We noticed that splenomegaly was detected more in short survival group, and the difference is of statistically significance (P<0.001). We also found that hypofibrinogenemia and LDH >1,000 U/L at diagnosis of HLH were also statistically significant different (P=0.026, P=0.007) between the two groups. Other factors such as gender, age at diagnosis of HLH, ECOG, stage, EBVencoded RNA (EBER) status, anemia, and thrombocytopenia were not statistically different between two groups ( Table 2 ).
The impact of patients' clinical and laboratory parameters on Os
Kaplan-Meier analysis indicated that patients with higher LDH at diagnosis of HLH had a lower OS compared to those with lower levels of LDH (P=0.002, Figure 2A ). An association was found between hypofibrinogenemia and a worse OS (P=0.003; Figure 2B ). Presence of splenomegaly was also correlated with a poor OS (P=0.003; Figure 2C ).
Discussion
The onset of HLH during or after the treatment of NK/T-cell lymphoma is a rare, but often catastrophic event. In most cases even intensive therapeutic measures cannot prevent the lethal outcome. 13 Therefore, it would be highly valuable to rapidly identify clinical and/or laboratory risk factors of the disease. Here, in this retrospective study, we concentrated on the clinical and laboratory features, and prognostic factors of NK/T-cell lymphoma patients diagnosed with HLH.
The mortality rate within 1 month after diagnosis of NHL-related HLH was reported as high as 20%.
14 NK/T-cell lymphoma had a worse prognosis than B-cell lymphoma, with 5-year survival rate of <15%. 15 In our study, mortality rate was 96.4% with only one patient survived, and the median survival was 15 days, which underscores the rapid progression and poor prognosis of the disease.
To clarify the increased risk for NK/T-cell lymphomaassociated HLH, we compared the patients' characteristics in our cohort with some previous studies. 9, 11 Table 3 indicates that increased risk for HLH was associated with higher ECOG scores (ECOG 2-3; P<0.001, P<0.001), primary site of involvement (EUNKTL; P<0.001, P=0.006), and cutaneous involvement (P<0.001). Previous studies have reported that splenomegaly and elevated LDH levels affect patient prognosis. 16, 17 Besides, in our study, we also found that hypofibrinogenemia was an adverse prognostic factor of HLH.
Treatment for NK/T-cell LAHS remains a challenge. In our study, we mainly carried out treatment according to HLH-04 guidelines. We found there was statistically significant difference between treatment response and patients' OS (P=0.00021), which was consistent with other previous reports. 5, 18 Previous reports also recommended that those who respond well with NK/T-cell LAHS initial induction therapy should be actively engaged in HSCT. 19, 20 However, even with the currently recommended therapy, HLH is frequently a fatal condition with a high rate of mortality. Also some investigators suggested doctors should simultaneously consider controlling high inflammatory cytokine storm and treating NK-T-cell lymphoma. 21 Further clinical trials should be carried out to explore better therapeutic procedures, especially for those who do not respond to first line treatment regimens.
There are some limitations of our study. First, because of the long period of study, the number of copies of EBV-DNA was not routinely detected; the association between the levels of EBV-DNA and patients' OS were not analyzed. Second, we only enrolled and analyzed hospitalized patients, the number of cases in this study was relatively small, and only one patient received HSCT. 
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Conclusion
In summary, NK/T-cell LAHS is highly lethal and with extremely poor prognosis. Our data indicated that the levels of LDH, fibrinogen, and presence of splenomegaly were prognostic factors of the disease. Higher ECOG scores, EUNKTL, and cutaneous involvement were risk factors of NK/T-cell LAHS. Additional independent, prospective clinical trials will be needed to explore optimal treatment.
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